Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SCPH Stock Forecast 2026-2027
$5.67
Current Price
$304.36M
Market Cap
Buy 0
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to SCPH Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
SCPH Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+14.8%
1 Year Change
0.0%
Year-to-Date Change
-9.7%
From 52W High of $6.28
+192.3%
From 52W Low of $1.94
📊 TOP ANALYST CALLS
Did SCPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Scpharmaceuticals is one of their latest high-conviction picks.
Latest SCPH Stock Price Targets & Analyst Predictions
SCPH has shown a year-to-date change of 0.0% and a 1-year change of 14.8%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for SCPH. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SCPH Analyst Ratings
0
Buy
2
Hold
0
Sell
SCPH Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $5.67
Latest SCPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SCPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 26, 2025 | Craig-Hallum | Chase Knickerbocker | Hold | Downgrade | $6.00 |
| Aug 25, 2025 | Maxim Group | Naz Rahman | Hold | Downgrade | $N/A |
| Mar 20, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 20, 2025 | Maxim Group | Naz Rahman | Buy | Maintains | $12.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Nov 14, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $12.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| May 15, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Sep 7, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $20.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Aug 2, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 19, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 8, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 11, 2023 | Maxim Group | Naz Rahman | Buy | Maintains | $20.00 |
| May 11, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Mar 23, 2023 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $18.00 |
| Jan 27, 2023 | SVB Leerink | Roanna Ruiz | Outperform | Maintains | $13.00 |
ScPharmaceuticals Inc. (SCPH) Competitors
The following stocks are similar to Scpharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SCPH
Scpharmaceuticals
mkt cap
304.36M
ScPharmaceuticals Inc. (SCPH) Financial Data
ScPharmaceuticals Inc. has a market capitalization of $304.36M with a P/E ratio of -3.0x. The company generates $49.97M in trailing twelve-month revenue with a -183.5% profit margin.
Revenue growth is +99.2% quarter-over-quarter, while maintaining an operating margin of -89.1% and return on equity of -639.2%.
Valuation Metrics
Market Cap
$304.36M
Enterprise Value
$313.56M
P/E Ratio
-3.0x
PEG Ratio
0.1x
Price/Sales
6.1x
Growth & Margins
Revenue Growth (YoY)
+99.2%
Gross Margin
+68.8%
Operating Margin
-89.1%
Net Margin
-183.5%
EPS Growth
+99.2%
Financial Health
Cash/Price Ratio
+13.6%
Current Ratio
3.9x
Debt/Equity
-2.5x
ROE
-639.2%
ROA
-57.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ScPharmaceuticals Inc. (SCPH) Business Model
About ScPharmaceuticals Inc.
What They Do
Develops innovative treatments for heart failure.
Business Model
The company focuses on creating user-friendly therapies for chronic conditions, particularly heart failure, that allow for self-administration at home. By simplifying the drug delivery process, ScPharmaceuticals aims to reduce hospital visits, thus generating revenue through the sale of its advanced pharmaceutical products and formulations.
Additional Information
ScPharmaceuticals is notable for its advanced subcutaneous formulations that enhance patient comfort and adherence, offering potential cost savings for healthcare systems. The company has established itself in the biotechnology and pharmaceuticals market by leveraging innovative research to address critical medical needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
162
CEO
Mr. John H. Tucker
Country
United States
IPO Year
2017
Website
www.scpharmaceuticals.comScPharmaceuticals Inc. (SCPH) Latest News & Analysis
Latest News
Quick Summary
scPharmaceuticals Inc. is being investigated regarding its proposed sale to MannKind Corporation. Shareholders would receive $5.35 per share plus a non-tradable contingent value right.
Why It Matters
The investigation into scPharmaceuticals' sale may indicate potential legal or valuation issues, impacting shareholder confidence and stock performance for both scPharmaceuticals and MannKind.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
MannKind Corporation will acquire scPharmaceuticals in a definitive merger agreement, announced on August 25, 2025. Both companies are listed on Nasdaq.
Why It Matters
The merger could enhance MannKind's product portfolio and market presence, impacting future revenue growth and operational efficiency, which may influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
10 months ago
Quick Summary
Wohl & Fruchter LLP is investigating the sale of scPharmaceuticals, Inc. to MannKind Corporation for $5.35 per share, plus a contingent value right for potential additional payments.
Why It Matters
Concerns over the fairness of scPharmaceuticals' sale may indicate potential undervaluation, impacting investor sentiment and the stock's market performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating scPharmaceuticals (SCPH) for potential breaches of fiduciary duty related to its transaction with MannKind. Shareholders will receive $5.35 per share plus contingent value rights.
Why It Matters
The investigation into scPharmaceuticals may raise concerns over potential legal issues and fiduciary breaches, impacting stock performance and shareholder confidence in the acquisition.
Source: Business Wire
Market Sentiment:
Neutral
SCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to Shareholders
10 months ago
Quick Summary
Halper Sadeh LLC is investigating the fairness of MannKind Corp's proposed acquisition of scPharmaceuticals Inc. Shareholders would receive $5.35 per share plus potential CVRs worth up to $1.00.
Why It Matters
The investigation into scPharmaceuticals' sale could impact share prices and investor sentiment, as fairness concerns may affect the deal's completion and valuation.
Source: Business Wire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders
10 months ago
Quick Summary
Halper Sadeh LLC is investigating several companies for possible violations of federal securities laws and breaches of fiduciary duties to shareholders. Further details on specific companies were not provided.
Why It Matters
Investigations by a law firm into potential securities law violations can signal risks for affected companies, impacting share prices and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SCPH Stock
What is ScPharmaceuticals Inc.'s (SCPH) stock forecast for 2027?
Analyst forecasts for ScPharmaceuticals Inc. (SCPH) are not currently available. The stock is trading at $5.67.
Is SCPH stock a good investment in 2027?
According to current analyst ratings, SCPH has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SCPH stock?
Price predictions from Wall Street analysts for SCPH are not currently available. The stock is trading at $5.67.
What is ScPharmaceuticals Inc.'s business model?
The company focuses on creating user-friendly therapies for chronic conditions, particularly heart failure, that allow for self-administration at home. By simplifying the drug delivery process, ScPharmaceuticals aims to reduce hospital visits, thus generating revenue through the sale of its advanced pharmaceutical products and formulations.
What is the highest forecasted price for SCPH ScPharmaceuticals Inc.?
Price targets from Wall Street analysts for SCPH are not currently available. The stock is trading at $5.67.
What is the lowest forecasted price for SCPH ScPharmaceuticals Inc.?
Price targets from Wall Street analysts for SCPH are not currently available. The stock is trading at $5.67.
What is the overall SCPH consensus from analysts for ScPharmaceuticals Inc.?
The overall analyst consensus for SCPH is neutral. Out of 9 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell.
How accurate are SCPH stock price projections?
Stock price projections, including those for ScPharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:21 PM UTC